Pemetrexed

Generic Name: Pemetrexed

Brand Names: Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₁N_₅O_₆

CAS Number: 137281-23-3

Unique Ingredient Identifier: 04Q9AIZ7NO

Background: Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...

Indication: Pemetrexed is indicated for the treatment of the following conditions:

Non-squamous non-small cell lung cancer (NSCLC)

Malignant pleural mesothelioma

Associated Conditions: Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma

Associated Therapies: Monotherapy

Clinical Trials

Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Pemetrexed
Other: Best Supportive Care

First Posted Date: 2005-02-02

Last Posted Date: 2014-12-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 663

Registration Number: NCT00102804

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey

A Study of Pemetrexed Plus Doxorubicin Given to Patients With Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2005-01-26

Last Posted Date: 2007-11-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 77

Registration Number: NCT00102219

Locations: 🇻🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Caracas, Venezuela

Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer

Phase 1

Completed

Conditions: Carcinoma, Transitional Cell

First Posted Date: 2005-01-17

Last Posted Date: 2006-08-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 61

Registration Number: NCT00101842

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician., Dallas, Texas, United States

Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Biological: Cetuximab
Drug: Pemetrexed
Drug: Docetaxel

First Posted Date: 2004-11-02

Last Posted Date: 2012-10-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 939

Registration Number: NCT00095199

Locations: 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., St-Jerome, Quebec, Canada

Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma

Phase 2

Completed

Conditions: Pleural Neoplasms

Interventions: Drug: pemetrexed
Drug: cisplatin

First Posted Date: 2004-07-16

Last Posted Date: 2009-05-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 77

Registration Number: NCT00087698

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Houston, Texas, United States

A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non Small Cell Lung Carcinoma

Interventions: Drug: pemetrexed
Drug: gemcitabine
Drug: cisplatin

First Posted Date: 2004-07-16

Last Posted Date: 2019-09-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1713

Registration Number: NCT00087711

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sutton, United Kingdom

Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

First Posted Date: 2004-03-19

Last Posted Date: 2007-11-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 120

Registration Number: NCT00079872

Locations: 🇪🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Sevilla, Spain

A Comparison of Two Doses of Pemetrexed in Patients Who Have Lung Cancer

Phase 3

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: pemetrexed

First Posted Date: 2004-02-24

Last Posted Date: 2019-09-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 589

Registration Number: NCT00078260

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gaziantep, Turkey

Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
Neoplasm Metastasis

First Posted Date: 2003-11-13

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 50

Registration Number: NCT00072865

Locations: 🇷🇺
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Saint Petersburg, Russia, Russian Federation

Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Lung Neoplasms

First Posted Date: 2003-10-16

Last Posted Date: 2007-01-26

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 48

Registration Number: NCT00071136

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY(1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC-GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy